Skip to main content
. 2014 Feb 27;2014:827415. doi: 10.1155/2014/827415

Figure 2.

Figure 2

The HER2 mRNA expression was stabilized in HBx-expressing HCC cells. (a) The two HBx-paired HCC cells were treated with proteasomal inhibitors (MG132 and bortezomib) for 24 hrs. The HER2 protein expression was analyzed by Western blot (N = 3). (b) The HER2 mRNA expression in two HBx-paired HCC cells was examined by RT-qPCR. The HER2 mRNA expression was normalized to actin expression. Statistical analysis was performed by Student's t-test. **P < 0.01; ***P < 0.001 as compared to each control group (N = 3). (c) The HepG2 and HepG2x HCC cells were treated with 5 μM Actinomycin D for indicated time periods. The relative remaining HER2 mRNA expression in each of the HCC cells was determined by RT-qPCR. The HER2 mRNA expression was normalized to actin expression (N = 4). (d) Hep3B HCC cells were transiently transfected with myc-HBx expression vector for 48 hrs, followed by treatment of 5 μM Actinomycin D. The relative remaining HER2 mRNA expression in each group was determined by RT-qPCR. The HER2 mRNA expression was normalized to actin expression. The protein expression of myc-HBx was confirmed by Western blot. Statistical analysis was performed by Student's t-test. **P < 0.01 as compared to each control group. N.S. denoted “not significant” (N = 4).